Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE
Relief Therapeutics announced the publication of a Plain Language Summary in Future Rare Diseases about PKU GOLIKE®, their treatment for phenylketonuria (PKU). The summary, co-authored by PKU specialists and patient associations, presents clinical study results comparing PKU GOLIKE® with standard amino acid formulations. The study showed that while both provide equal amino acid levels, PKU GOLIKE® delivers a more natural absorption pattern, similar to whole food proteins. This sustained absorption benefits PKU patients who need stable amino acid intake for metabolic balance. The publication aims to make complex scientific information more accessible to patients and caregivers.
Relief Therapeutics ha annunciato la pubblicazione di un Riassunto in Linguaggio Semplice in Future Rare Diseases riguardo a PKU GOLIKE®, il loro trattamento per la fenilchetonuria (PKU). Il riassunto, co-autore da specialisti della PKU e associazioni di pazienti, presenta i risultati di studi clinici che confrontano PKU GOLIKE® con formulazioni standard di aminoacidi. Lo studio ha mostrato che, sebbene entrambi forniscano livelli equivalenti di aminoacidi, PKU GOLIKE® offre un pattern di assorbimento più naturale, simile a quello delle proteine alimentari intere. Questo assorbimento sostenuto avvantaggia i pazienti PKU che necessitano di un'assunzione stabile di aminoacidi per un equilibrio metabolico. La pubblicazione ha l'obiettivo di rendere le informazioni scientifiche complesse più accessibili a pazienti e caregiver.
Relief Therapeutics anunció la publicación de un Resumen en Lenguaje Sencillo en Future Rare Diseases sobre PKU GOLIKE®, su tratamiento para la fenilcetonuria (PKU). El resumen, co-escrito por especialistas en PKU y asociaciones de pacientes, presenta los resultados de estudios clínicos que comparan PKU GOLIKE® con formulaciones estándar de aminoácidos. El estudio mostró que, aunque ambos proporcionan niveles equivalentes de aminoácidos, PKU GOLIKE® ofrece un patrón de absorción más natural, similar al de las proteínas de alimentos completos. Esta absorción sostenida beneficia a los pacientes con PKU que necesitan una ingesta estable de aminoácidos para mantener el equilibrio metabólico. La publicación tiene como objetivo hacer que la información científica compleja sea más accesible para pacientes y cuidadores.
Relief Therapeutics는 미래 희귀 질환(Future Rare Diseases)에서 페닐케톤뇨증(PKU) 치료제인 PKU GOLIKE®에 대한 간단한 언어 요약을 발표했다고 밝혔습니다. 이 요약은 PKU 전문가와 환자 협회가 공동 저자로 참여하였으며, PKU GOLIKE®와 표준 아미노산 제제를 비교한 임상 연구 결과를 담고 있습니다. 연구 결과, 두 제품 모두 동일한 아미노산 수준을 제공하지만, PKU GOLIKE®는 전체 식품 단백질과 유사한 자연스러운 흡수 패턴을 제공합니다. 이러한 지속적인 흡수는 대사 균형을 위해 안정적인 아미노산 섭취가 필요한 PKU 환자에게 이점을 줍니다. 이번 출판은 복잡한 과학 정보를 환자와 간병인이 보다 쉽게 이해할 수 있도록 하는 것을 목표로 합니다.
Relief Therapeutics a annoncé la publication d'un Résumé en Langage Simple dans Future Rare Diseases concernant PKU GOLIKE®, leur traitement pour la phénylcétonurie (PKU). Le résumé, coécrit par des spécialistes de la PKU et des associations de patients, présente les résultats d'études cliniques comparant PKU GOLIKE® aux formulations standard d'acides aminés. L'étude a montré que, bien que les deux fournissent des niveaux équivalents d'acides aminés, PKU GOLIKE® offre un schéma d'absorption plus naturel, similaire à celui des protéines d'aliments entiers. Cette absorption soutenue bénéficie aux patients atteints de PKU qui ont besoin d'un apport stable d'acides aminés pour un équilibre métabolique. La publication vise à rendre les informations scientifiques complexes plus accessibles aux patients et aux aidants.
Relief Therapeutics hat die Veröffentlichung einer Zusammenfassung in einfacher Sprache in Future Rare Diseases über PKU GOLIKE®, ihre Behandlung für Phenylketonurie (PKU), bekannt gegeben. Die Zusammenfassung, die von PKU-Spezialisten und Patientenverbänden co-authored wurde, präsentiert die Ergebnisse klinischer Studien, die PKU GOLIKE® mit Standard-Aminosäureformulierungen vergleichen. Die Studie hat gezeigt, dass beide zwar gleichwertige Aminosäurewerte liefern, PKU GOLIKE® jedoch ein natürlicheres Absorptionsmuster bietet, das dem von Vollwertproteinen ähnelt. Diese anhaltende Absorption kommt PKU-Patienten zugute, die eine stabile Aminosäureaufnahme für ein metabolisches Gleichgewicht benötigen. Die Veröffentlichung zielt darauf ab, komplexe wissenschaftliche Informationen für Patienten und Pflegekräfte zugänglicher zu machen.
- Clinical study demonstrates PKU GOLIKE® provides more natural absorption pattern compared to standard treatments
- Product shows improved sustained absorption benefits for PKU patients
- None.
GENEVA, SWITZARLAND / ACCESSWIRE / October 29, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, announced the publication of a Plain Language Summary in Future Rare Diseases highlighting findings on PKU GOLIKE ® for phenylketonuria (PKU) management. Titled "The Benefits of a Prolonged-Release Protein Substitute with Similarities to Natural Proteins as a Treatment for Phenylketonuria," the summary was co-authored by PKU specialists with insights from patient associations, translating complex clinical insights for a broad audience. The article is available here.
Summarizing findings previously published in Nutrients , this Plain Language Summary presents results from a clinical study comparing PKU GOLIKE ® , Relief's prolonged-release amino acid mix, with a standard amino acid formulation. The results showed that while both mixtures provide the same total amino acid levels, PKU GOLIKE ® offers a more natural absorption pattern, closely resembling the release of proteins from whole foods. This sustained absorption benefits individuals with PKU who rely on stable amino acid intake for metabolic balance.
Plain Language Summaries play an important role in bridging the gap between scientific research and public understanding. By enhancing public comprehension of complex studies, these summaries raise awareness of a study's impact and promote the active involvement of patients and caregivers. "Our core value as a rare disease pharma company is patient centricity, putting patients at the heart of drug development," said Patrizia Marzorati, Head of Medical Affairs at Relief. "Creating accessible information and resources that meet patient needs is one of our strategies to foster inclusion. By helping patients and caregivers understand scientific information, we aim to support both compliance and acceptance of dietary management in PKU."
ABOUT PKU GOLIKE ®
PKU GOLIKE products are Foods for Special Medical Purposes (FSMPs) for the dietary management of PKU in children and adults. Developed with Relief's proprietary, patent-protected Physiomimic Technology™ drug delivery platform, PKU GOLIKE products are the first prolonged-release amino acid FSMPs, characterized by a special coating that ensures physiological absorption of the amino acids mirroring that of natural proteins, while also masking the unpleasant taste and odor typically associated with amino acids. PKU GOLIKE products are marketed in the U.S. by Eton Pharmaceuticals Inc. under an exclusive license and supply agreement with Relief, in key European markets by Relief, and in select countries worldwide through licensing and distribution partners.
ABOUT RELIEF
Relief is a commercial-stage biopharmaceutical company committed to advancing treatment paradigms and delivering improvements in efficacy, safety, and convenience to benefit the lives of patients living with select specialty and rare diseases. Relief's portfolio offers a balanced mix of marketed, revenue-generating products, proprietary, globally patented TEHCLO™ and Physiomimic™ platform technologies and a targeted clinical development pipeline consisting of risk-mitigated assets focused in three core therapeutic areas: rare skin diseases, rare metabolic disorders, and rare respiratory diseases. In addition, Relief is commercializing several legacy products via licensing and distribution partners. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com.
CONTACT :
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Chief Financial Officer
contact@relieftherapeutics.com
DISCLAIMER
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, including its ability to achieve its corporate, development and commercial goals, and other factors which could cause the actual results, financial condition, performance or achievements of Relief to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. A number of factors, including those described in Relief's filings with the SIX Swiss Exchange and the U.S. Securities and Exchange Commission (SEC), could adversely affect Relief. Copies of Relief's filings with the SEC are available on the SEC EDGAR database at www.sec.gov . Relief does not undertake any obligation to update the information contained herein, which speaks only as of this date.
SOURCE: Relief Therapeutics Holding SA
View the original press release on accesswire.com
FAQ
What are the clinical benefits of PKU GOLIKE (RLFTF) compared to standard amino acid formulations?
What is the purpose of Relief Therapeutics' (RLFTF) Plain Language Summary publication?
Where was Relief Therapeutics' (RLFTF) PKU GOLIKE study published?
